Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q4 2018 · 10-K
Revenue$73.43M$73.43M+580.3% vs Q4 2017 Net Income$9.09M$9.09MN/M vs Q4 2017 EPS Diluted$0.27$0.27N/M vs Q4 2017 Operating Income$11,001,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$40,515,000N/M Margins · derivedOperating margin15.0%+177.9 pt vs Q4 2017
Net margin12.4%+173.6 pt vs Q4 2017
ended Dec 31, 2018 · filed Feb 27, 2019 · 58 d after period end